People: Alnylam Pharmaceuticals Inc (ALNY.O)
ALNY.O on Nasdaq
27.44USD
17 May 2013
27.44USD
17 May 2013
Price Change (% chg)
$0.23 (+0.85%)
$0.23 (+0.85%)
Prev Close
$27.21
$27.21
Open
$27.24
$27.24
Day's High
$27.89
$27.89
Day's Low
$27.04
$27.04
Volume
520,072
520,072
Avg. Vol
441,712
441,712
52-wk High
$28.68
$28.68
52-wk Low
$9.51
$9.51
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Clarke |
58 | 2002 | Independent Chairman of the Board |
Barry Greene |
49 | 2007 | President, Chief Operating Officer |
John Maraganore |
50 | 2007 | Chief Executive Officer, Director |
Akshay Vaishnaw |
50 | 2012 | Executive Vice President, Chief Medical Officer |
Laurence Reid |
49 | 2010 | Senior Vice President, Chief Business Officer |
Michael Mason |
38 | 2011 | Vice President - Finance, Treasurer |
Dennis Ausiello |
67 | 2012 | Director |
Phillip Sharp |
67 | 2002 | Director |
Victor Dzau |
67 | 2007 | Independent Director |
Marsha Fanucci |
58 | 2010 | Independent Director |
Steven Paul |
62 | 2010 | Independent Director |
Paul Schimmel |
71 | 2002 | Independent Director |
Kevin Starr |
49 | 2003 | Independent Director |
Biographies
| Name | Description |
|---|---|
John Clarke |
Mr. John K. Clarke is Independent Chairman of the Board of Alnylam Pharmaceuticals, Inc. Mr. Clarke is a founder of Alnylam and has served as the chairman of board of directors since June 2002. Since founding Cardinal Partners, a venture capital firm focused on healthcare, in 1997, Mr. Clarke has served as its Managing General Partner. Mr. Clarke also serves as a director of Momenta Pharmaceuticals, Inc. and Verastem, Inc., and formerly served as a director of Sirtris Pharmaceuticals, Inc. and Visicu, Inc. |
Barry Greene |
Mr. Barry E. Greene is President, Chief Operating Officer of Alnylam Pharmaceuticals, Inc. He has served as President and Chief Operating Officer since December 2007, as Chief Operating Officer since he joined in October 2003, and from February 2004 through December 2005, as Treasurer. From February 2001 to September 2003, Mr. Greene served as General Manager of Oncology at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Greene serves as a member of the board of directors of Acorda Therapeutics, Inc., a biotechnology company. |
John Maraganore |
Dr. John M. Maraganore, Ph.D., is Chief Executive Officer, Director of Alnylam Pharmaceuticals, Inc. Dr. Maraganore has served as Chief Executive Officer and as a member of board of directors since December 2002. Dr. Maraganore also served as President from December 2002 to December 2007. From April 2000 to December 2002, Dr. Maraganore served as Senior Vice President, Strategic Product Development for Millennium Pharmaceuticals, Inc., a biopharmaceutical company. He also serves as a director of the Biotechnology Industry Organization. |
Akshay Vaishnaw |
Dr. Akshay K. Vaishnaw, M.D., Ph.D., is Executive Vice President, Chief Medical Officer of Alnylam Pharmaceuticals, Inc., since June 21, 2012. Dr. Vaishnaw has been with the Company since January 2006 and has most recently served as the Company’s Senior Vice President and Chief Medical Officer since June 2011. From December 2008 until June 2011, Dr. Vaishnaw served as the Company’s Senior Vice President, Clinical Research and from January 2006 until December 2008 was the Company’s Vice President, Clinical Research. |
Laurence Reid |
Dr. Laurence E. Reid, Ph.D., is Senior Vice President, Chief Business Officer of Alnylam Pharmaceuticals, Inc., since June 2, 2010. From January 2006 through May 2010, Dr. Reid served as the Chief Business Officer at Ensemble Therapeutics, a biotechnology company. Prior to joining Ensemble Therapeutics, Dr. Reid worked as a founder of two start-up companies in the fields of stem cell therapeutics and inflammation. Dr. Reid previously spent ten years at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, from 1993 through 2003, where he served in a range of general management and business development positions, including General Manager of Millennium UK with responsibility for Millennium’s European operations, Vice President of Business Development and Strategic Planning for the company’s predictive medicine efforts, as well as in pharmaceutical business development and technology acquisition. |
Michael Mason |
Mr. Michael P. Mason is Vice President - Finance, Treasurer of Alnylam Pharmaceuticals, Inc., since February 28, 2011. From December 2005 to February 2011, Mr. Mason served as Corporate Controller, and from August 2009 to February 2011, as Senior Director of Finance. From June 2006 to July 2009, Mr. Mason served as Director of Finance. From May 2000 through November 2005, Mr. Mason served in several finance and commercial roles at Praecis Pharmaceuticals Incorporated, a public biotechnology company, most recently as Corporate Controller. Prior to Praecis, Mr. Mason worked in the audit practice at KPMG LLP, a national audit, tax and advisory services firm. Mr. Mason has an MBA and is a certified public accountant. |
Dennis Ausiello |
Dr. Dennis A. Ausiello, M.D., is Director of Alnylam Pharmaceuticals, Inc., since April 20, 2012. Dr. Ausiello has served as a member of board of directors since April 2012. Dr. Ausiello serves as the Jackson Professor of Clinical Medicine at Harvard Medical School and has served as the Chief of Medicine at Massachusetts General Hospital since 1996. Dr. Ausiello was the President of the Association of American Physicians in 2006. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. He also serves as a director of Pfizer Inc. Dr. Ausiello received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania. |
Phillip Sharp |
Dr. Phillip A. Sharp, Ph.D., is Director of Alnylam Pharmaceuticals, Inc. Dr. Sharp is a scientific founder of Alnylam and has served as a member of board of directors since June 2002. Dr. Sharp is an Institute Professor at the David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), and was the Founding Director of the McGovern Institute for Brain Research at MIT. Dr. Sharp has been a professor at MIT since 1974. He is a member of the National Academy of Sciences, the Institute of Medicine and American Academy of Arts and Sciences. Dr. Sharp also formerly served as a director of Biogen, Inc. (now Biogen Idec Inc.), a biotechnology company, which he co-founded in 1978. |
Victor Dzau |
Dr. Victor J. Dzau, M.D., is Independent Director of Alnylam Pharmaceuticals, Inc., since April 4, 2007. Dr. Dzau has been the Chancellor for Health Affairs at Duke University and President and Chief Executive Officer of the Duke University Health System since July 2004. From July 1996 to September 2004, he was the Hersey Professor of Theory and Practice of Medicine at Harvard Medical School and Chair of the Department of Medicine, Physician in Chief and Director of Research at Brigham and Women’s Hospital. He is a former Chairman of the National Institutes of Health (NIH) Cardiovascular Disease Advisory Committee and served on the Advisory Committee to the Director of the NIH. He is a member of the Institute of Medicine. He also serves as a director of Duke University Health System, Medtronic, Inc., PepsiCo, Inc. and Genzyme Corporation. |
Marsha Fanucci |
Ms. Marsha H. Fanucci is Independent Director of Alnylam Pharmaceuticals, Inc. Ms. Fanucci has served as a member of board of directors since December 2010. Ms. Fanucci served as Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company, from July 2004 to January 2009. While at Millennium, she also served as Vice President, Finance and Corporate Strategy from July 2003 to June 2004, and prior to that as Vice President of Corporate Development from 2000. Prior to joining Millennium, Ms. Fanucci served as Vice President of Corporate Development and Strategy at Genzyme Corporation, a biotechnology company, from 1998 to 2000. Ms. Fanucci also serves as a director of Ironwood Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc. |
Steven Paul |
Dr. Steven M. Paul, M.D., is Independent Director of Alnylam Pharmaceuticals, Inc. Dr. Paul has served as a member of board of directors since September 2010. Dr. Paul is the Director of the Appel Alzheimer’s Disease Research Institute and a Professor of Neurology (Neuroscience), Psychiatry and Pharmacology at Weill Cornell Medical College of Cornell University. Dr. Paul served for 17 years at Eli Lilly and Company, a pharmaceutical company, most recently as the Executive Vice President for Science and Technology and President of the Lilly Research Laboratories, a division of Eli Lilly and Company, from July 2003 to his retirement in February 2010. Prior to this, he served as Group Vice President of Therapeutic Area Discovery Research and Clinical Investigation for Lilly Research Laboratories for more than five years. He is a member the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Association for the Advancement of Science. Prior to joining Lilly, Dr. Paul served in several senior roles at the National Institute of Mental Health, including serving as the Scientific Director of the Intramural Research Program. Dr. Paul also serves as a director of the Sigma-Aldrich Corporation and the Foundation of the National Institutes of Health, and is a Venture Partner at Third Rock Ventures, a venture capital firm. |
Paul Schimmel |
Dr. Paul R. Schimmel, Ph.D., is Independent Director of Alnylam Pharmaceuticals, Inc. Dr. Schimmel is a scientific founder of Alnylam and has served as a member of board of directors since June 2002. Dr. Schimmel has been the Ernest and Jean Hahn Professor of Molecular Biology and Chemistry and a member of the Skaggs Institute for Chemical Biology at the Scripps Research Institute since 1997. Dr. Schimmel is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. |
Kevin Starr |
Mr. Kevin P. Starr is Independent Director of Alnylam Pharmaceuticals, Inc. Mr. Starr has served as a member of board of directors since September 2003. Since April 2007, Mr. Starr has been a Partner of Third Rock Ventures, a venture capital firm. From December 2002 to March 2007, Mr. Starr was an entrepreneur. From December 2001 to December 2002, Mr. Starr served as Chief Operating Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company. He also served as Millennium’s Chief Financial Officer from December 1998 to December 2002. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Clarke |
-- |
Barry Greene |
952,486 |
John Maraganore |
1,398,180 |
Akshay Vaishnaw |
1,123,350 |
Laurence Reid |
574,188 |
Michael Mason |
490,560 |
Dennis Ausiello |
-- |
Phillip Sharp |
-- |
Victor Dzau |
-- |
Marsha Fanucci |
-- |
Steven Paul |
-- |
Paul Schimmel |
-- |
Kevin Starr |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
John Clarke |
0 | 0 |
Barry Greene |
282,658 | 2,793,479 |
John Maraganore |
1,171,314 | 10,768,750 |
Akshay Vaishnaw |
0 | 0 |
Laurence Reid |
0 | 0 |
Michael Mason |
0 | 0 |
Dennis Ausiello |
0 | 0 |
Phillip Sharp |
0 | 0 |
Victor Dzau |
0 | 0 |
Marsha Fanucci |
0 | 0 |
Steven Paul |
0 | 0 |
Paul Schimmel |
0 | 0 |
Kevin Starr |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
STARR KEVIN P |
26,000 | $23.41 |
STARR KEVIN P |
26,000 | $0.95 |
STARR KEVIN P |
26,631 | $0.95 |
STARR KEVIN P |
26,631 | $23.56 |
GREENE BARRY E |
24,058 | $0.95 |
GREENE BARRY E |
24,058 | $25.00 |
VAISHNAW AKSHAY K |
6,250 | $24.55 |
VAISHNAW AKSHAY K |
6,250 | $9.30 |
GREENE BARRY E |
24,000 | $0.95 |
GREENE BARRY E |
24,000 | $24.43 |
MARAGANORE JOHN M |
28,503 | $23.50 |
MARAGANORE JOHN M |
30,000 | $23.47 |
REID LAURENCE E |
5,000 | $25.00 |
REID LAURENCE E |
5,000 | $7.10 |
SHARP PHILLIP A |
4,967 | $20.13 |
MARAGANORE JOHN M |
14,102 | $0.48 |
MARAGANORE JOHN M |
4,515 | $0.48 |
VAISHNAW AKSHAY K |
10,000 | $19.00 |
VAISHNAW AKSHAY K |
6,250 | $9.30 |
VAISHNAW AKSHAY K |
3,750 | $9.14 |
VAISHNAW AKSHAY K |
4,777 | $7.10 |
VAISHNAW AKSHAY K |
4,777 | $17.00 |
VAISHNAW AKSHAY K |
2,400 | $7.10 |
VAISHNAW AKSHAY K |
2,400 | $17.04 |
MASON MICHAEL P |
3,750 | $16.93 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
